Clinical trials: sponsored by Merck Sharp & Dohme LLC
Asthma
Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)
This research study was designed to help improve the diagnosis and treatment of asthma in young children. An interventional strategy using a scoring system based on risk factors and symptoms/episodes was tested to determine its…
- Trial name
- NCT00211575
- Testing
- Disease Management Assessment
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasm
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).
- Trial name
- NCT00736333
- Testing
- Pegylated Liposomal Doxorubicin
- Volunteers
- 167 people
- Sponsor
- Merck Sharp & Dohme LLC
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis.
- Trial name
- NCT00105469
- Testing
- AzaSite, Tobramycin
- Where
- 26 sites in United States
- Volunteers
- 743 people
- Sponsor
- Merck Sharp & Dohme LLC
Blepharitis
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)
The purpose of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% versus vehicle over a four-week treatment period in treating the signs and symptoms of subjects with blepharitis and to…
- Trial name
- NCT01269658
- Testing
- Azithromycin ophthalmic solution, 1%, Vehicle
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis.
- Trial name
- NCT00105534
- Testing
- AzaSite, Vehicle
- Where
- 32 sites in United States
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis
A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
The purpose of this study is to investigate the safety and effectiveness of two dose strengths of study drug compared to placebo in pediatric patients with cystic fibrosis (CF).
- Trial name
- NCT00130182
- Testing
- denufosol tetrasodium (INS37217)
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS)
Phase 2 Study in Patients With MiT Tumors
This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors.
- Conditions
- Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
- Trial name
- NCT00557609
- Testing
- ARQ 197
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 47 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
HIV Infections
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
- Trial name
- NCT00002406
- Testing
- Indinavir sulfate
- Where
- 29 sites in United States
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
- Trial name
- NCT00002235
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the level of HIV in the blood.
- Trial name
- NCT00002241
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
- Trial name
- NCT00002430
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 46 sites in United States
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
To demonstrate that the antiviral activity and safety/tolerability of a test regimen of indinavir is equivalent to that of a control regimen of indinavir when each is coadministered with zidovudine (ZDV) (or stavudine, d4T) and…
- Trial name
- NCT00002208
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 15 sites in United States
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of L-735,524 in HIV-Positive Children and Adolescents
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate ( MK-639; Crixivan ) in HIV-seropositive older children and adolescents.
- Trial name
- NCT00002351
- Testing
- Indinavir sulfate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor…
- Trial name
- NCT00002220
- Testing
- Indinavir sulfate, Efavirenz, Levocarnitine
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC